GENENTA SCIENCE SPA - ADR (GNTA) Stock News

NASDAQ:GNTA - Nasdaq - US36870W1009 - ADR - Currency: USD

3.49 -0.22 (-5.95%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GNTA Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: CNC SBFM SNGX SCNI ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

a month ago - By: Benzinga - Mentions: GOVX SNGX OGEN PULM ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

a month ago - By: GENENTA SCIENCE SPA

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

a month ago - By: GENENTA SCIENCE SPA

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

3 months ago - By: GENENTA SCIENCE SPA; Anemocyte

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

4 months ago - By: GENENTA SCIENCE SPA

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

4 months ago - By: GENENTA SCIENCE SPA

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

5 months ago - By: GENENTA SCIENCE SPA

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

5 months ago - By: GENENTA SCIENCE SPA

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

7 months ago - By: GENENTA SCIENCE SPA

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

7 months ago - By: GENENTA SCIENCE SPA

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

7 months ago - By: Italian Trade Agency

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

10 months ago - By: GENENTA SCIENCE SPA

Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

10 months ago - By: GENENTA SCIENCE SPA

Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

10 months ago - By: GENENTA SCIENCE SPA

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

10 months ago - By: GENENTA SCIENCE SPA

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

a year ago - By: InvestorPlace - Mentions: FGEN NVCT RLMD ANIX ...

7 Penny Biotech Stocks to Triple Your Investment

a year ago - By: GENENTA SCIENCE SPA

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

a year ago - By: GENENTA SCIENCE SPA - Mentions: ARYD SQZ

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

2 years ago - By: GENENTA SCIENCE SPA

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

2 years ago - By: GENENTA SCIENCE SPA

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

2 years ago - By: GENENTA SCIENCE SPA

Genenta to Present at Upcoming Scientific and Investor Conferences

2 years ago - By: GENENTA SCIENCE SPA

Genenta to Present at Upcoming Scientific and Investor Conferences

2 years ago - By: GENENTA SCIENCE SPA

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

2 years ago - By: GENENTA SCIENCE SPA

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

2 years ago - By: GENENTA SCIENCE SPA

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

2 years ago - By: GENENTA SCIENCE SPA

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

2 years ago - By: GENENTA SCIENCE SPA

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

2 years ago - By: Genenta Science

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

2 years ago - By: Genenta Science

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

3 years ago - By: Genenta Science

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement